Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.45 and traded as high as $2.59. Galectin Therapeutics shares last traded at $2.11, with a volume of 455,660 shares.
Wall Street Analyst Weigh In
Several equities research analysts have commented on GALT shares. HC Wainwright started coverage on shares of Galectin Therapeutics in a research note on Tuesday, June 17th. They issued a "buy" rating and a $6.00 price objective for the company. Wall Street Zen raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st.
Check Out Our Latest Stock Report on GALT
Galectin Therapeutics Trading Up 5.2%
The stock has a market cap of $140.50 million, a P/E ratio of -3.08 and a beta of 0.54. The stock's fifty day moving average price is $1.58 and its 200 day moving average price is $1.45.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.05. On average, analysts anticipate that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.
Institutional Trading of Galectin Therapeutics
Several large investors have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new position in Galectin Therapeutics during the first quarter valued at $287,000. LPL Financial LLC raised its stake in Galectin Therapeutics by 69.6% during the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company's stock valued at $179,000 after buying an additional 57,020 shares during the last quarter. HighTower Advisors LLC boosted its position in Galectin Therapeutics by 244.1% in the first quarter. HighTower Advisors LLC now owns 77,375 shares of the company's stock worth $94,000 after purchasing an additional 54,889 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Galectin Therapeutics by 8.8% during the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company's stock valued at $516,000 after buying an additional 34,300 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Galectin Therapeutics by 94.9% in the 4th quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company's stock worth $77,000 after purchasing an additional 29,065 shares during the period. 11.68% of the stock is owned by institutional investors.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
See Also
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
